The global biotechnology sector is on track to become a multi-trillion dollar industry.
The major factors driving this growth are a strong clinical pipeline of precision medicine and regenerative technologies, as well as a rising demand for treatments for chronic diseases such as cancer, diabetes and neurological disorders.
Year-to-date gain: 284.06 percent; market cap: AU$193.79 million; share price: AU$1.325
Year-to-date gain: 80.72 percent; market cap: AU$35.65 million; share price: AU$0.135
Year-to-date gain: 62 percent; market cap: AU$104.89 million; share price: AU$0.81
Shares in Argenica have experienced a degree of volatility for the first half of the year, trading in a range of AU$0.47 to AU$0.67 before jumping to AU$0.88 on June 19 and on to a year-to-date high of AU$0.93 on July 8.
Argenica’s shares have managed to stay above the AU$0.80 level for much of the third quarter to date.
Year-to-date gain: 61.54 percent; market cap: AU$36.11 million; share price: AU$0.21
Biotech penny stock Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company developing cell therapies based on its proprietary therapeutic stem cell platform technology, Cymerus. Its clinical pipeline includes a variety of indications such as graft-versus-host disease (GvHD), osteoarthritis, diabetic wounds and acute respiratory distress syndrome.
“Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60 (percent),” stated the press release. Shares in Cynata went on to hit its year-to-date peak of AU$0.34 on May 31.
Year-to-date gain: 8.48 percent; market cap: AU$442.1 million; share price: AU$0.36
The last ASX small cap biotech company on this list is Immutep, which is focused on developing autoimmune and cancer immunotherapy treatments. Its drug pipeline is built around eftilagimod alpha, its proprietary lymphocyte activation gene-3 (LAG-3) protein, an immune checkpoint molecule involved in the regulation of the immune system. LAG-3 was discovered by Immutep Chief Scientific Officer Frédéric Triebel.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Leave a Reply